0000000000150199

AUTHOR

Carlos Bea

showing 2 related works from this author

Impact of Acute Hemoglobin Falls in Heart Failure Patients: A Population Study

2020

Aims: This study assessed the impact of acute hemoglobin (Hb) falls in heart failure (HF) patients. Methods: HF patients with repeated Hb values over time were included. Falls in Hb greater than 30% were considered to represent an acute episode of anemia and the risk of hospitalization and all-cause mortality after the first episode was assessed. Results: In total, 45,437 HF patients (54.9% female, mean age 74.3 years) during a follow-up average of 2.9 years were analyzed. A total of 2892 (6.4%) patients had one episode of Hb falls, 139 (0.3%) had more than one episode, and 342 (0.8%) had concomitant acute kidney injury (AKI). Acute heart failure occurred in 4673 (10.3%) patients, represent…

medicine.medical_specialtyAnemiaheart failurelcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineRisk of mortality030212 general & internal medicineblood lossFirst episodebusiness.industryHazard ratiolcsh:RAcute kidney injuryGeneral Medicinemedicine.diseaseanemiamortalityConfidence interval3. Good healthacute kidney injuryConcomitantHeart failurebusinesshospitalizationJournal of Clinical Medicine
researchProduct

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation

2022

AimsTo assess the impact of anticoagulant treatment on risk for stroke and all-cause mortality of patients with atrial fibrillation using real-world data (RWD).MethodsPatients with prevalent or incident atrial fibrillation were selected throughout a study period of 5 years. Stroke, transitory ischemic attack, hemorrhagic stroke, and all-cause mortality were identified in the claims of the electronic health records (EHRs). Subjects were classified according to the anticoagulant treatment in four groups: untreated, vitamin K antagonists (VKAs), New Oral Anticoagulants (NOACs), and antiplatelet (AP). Risk of events and protection with anticoagulant therapy were calculated by Cox proportional h…

anticoagulant therapyRC666-701VKADiseases of the circulatory (Cardiovascular) systematrial fibrillationNOACsCardiovascular MedicineantiplateletCardiology and Cardiovascular MedicinestrokemortalityOriginal ResearchFrontiers in Cardiovascular Medicine
researchProduct